1. 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (23rd October 2018) Authors: Garralda, E; van Hoef, M; Ochsenreither, S; Gianni, L; Lorusso, D; Fiedler, W; Keilholz, U; Klinghammer, K; Dicke, C; Kebenko, M; Matos, I; Tabernero, J; Raspagliesi, F; Del Conte, G; Habel, B; Baumeister, H; Zurlo, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗